Royal Bank Of Canada upgraded shares of Illumina (NASDAQ:ILMN – Free Report) to a moderate buy rating in a research note published on Thursday,Zacks.com reports.
A number of other analysts also recently commented on the stock. UBS Group reissued a “neutral” rating and set a $135.00 price objective on shares of Illumina in a report on Friday, February 6th. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday. Canaccord Genuity Group lowered their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Evercore reiterated an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Finally, Guggenheim increased their price target on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $137.75.
Read Our Latest Analysis on ILMN
Illumina Stock Down 0.5%
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts expect that Illumina will post 5.2 earnings per share for the current fiscal year.
Insider Activity
In other news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Keith A. Meister sold 104,393 shares of the stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the completion of the sale, the director owned 3,500,048 shares in the company, valued at $508,696,976.32. This represents a 2.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 332,530 shares of company stock worth $48,303,655 over the last ninety days. 2.90% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Illumina
Several institutional investors and hedge funds have recently modified their holdings of ILMN. Capital World Investors lifted its stake in shares of Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after buying an additional 3,331,542 shares during the period. WCM Investment Management LLC lifted its stake in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares during the period. Invesco Ltd. lifted its stake in shares of Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after buying an additional 1,352,731 shares during the period. AQR Capital Management LLC lifted its stake in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after buying an additional 1,028,099 shares during the period. Finally, Morgan Stanley lifted its stake in shares of Illumina by 66.0% during the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after buying an additional 1,005,474 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.
About Illumina
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Articles
- Five stocks we like better than Illumina
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
